dc.relation.reference | 1. (a) Comprehensive Supramolecular Chemistry, Atwood, J. L., Davies, J. E., MacNicol, D. D., Vögtle, F., Reinhoudt, D. N., Lehn, J.-M., Eds.; Pergamon-Elsevier Science, Oxford, 1996. (b) Supramolecular Chemistry of Anions (Bianchi, A., Bowman-James, K., GarcKa-EspaLa, E.), Eds.; Wiley-VCH: New York, 1997.
2. (a) Lavigne, J. J.; Anslyn, E. V. Angew. Chem., Int. Ed. 2001, 40, 3118–3130. “Sensing a paradigm shift in the field of molecular recognition: from selective to differential receptors” (b) Wright, A. T.; Anslyn, E. V. Chem. Soc. Rev. 2006, 35, 14–28. “Differential receptor arrays and assays for solution-based molecular recognition”
3. (a) Suksai, C.; Tuntulani, T. Top. Curr. Chem. 2005, 255, 163–198. “Chromogenic anion sensors” (b) Martínez-Máñez1, R.; Sancenón, F. J. Fluoresc. 2005, 15, 267–285. “New advances in fluorogenic anion chemosensors”
4. (a) Schmidtchen, F. P.; Berger, M. Chem. Rev. 1997, 97, 1609–1646. “Artificial organic host molecules for anions“ (b) Beer, P. D.; Gale, P. A. Angew. Chem. Int. Ed. 2001, 40, 486–516. “Anion recognition and sensing: the state of the art and future perspectives” (c) Suksai, C.; Tuntulani, T. Chem. Soc. Rev. 2003, 32, 192–202. “Chromogenic anion sensors” (d) Martínez-Máñez, R.; Sancenón, F. Chem. Rev. 2003, 103, 4419–4476. “Fluorogenic and chromogenic chemosensors and reagents for anions”
5. Yamamura, S. S.; Wade, M. A.; Sikes, J. H. Anal. Chem. 1962, 34, 1308–1312. “Direct spectrophotometric fluoride determination”
6. Kata, R.; Nishizawa, S.; Hayashita, T.; Teramae, N. Tetrahedron Lett. 2001, 42, 5053–5056. “A thiourea-based chromoionophore for selective binding and sensing of acetate”
7. Lavigne, J. J.; Anslyn, E. V. Angew. Chem. Int. Ed. 1999, 38, 3666–3669. “Teaching old indicators new tricks: a colorimetric chemosensing ensemble for tartrate/malate in beverages”
8. (a) Gunnlaugsson, T.; Davis, A. P.; O’Brien, J. E.; Glynn, M. Org. Lett. 2002, 4, 2449–2452. “Fluorescent sensing of pyrophosphate and bis-carboxylates with charge neutral PET chemosensors” (b) Beer, P. D. Acc. Chem. Res. 1998, 31, 71–80. “Transition-metal receptor systems for the selective recognition and sensing of anionic guest species” (c) Liao, J. H.; Chen, C. T.; Fang, J. M. Org. Lett. 2002, 4, 561–564. “A novel phosphate chemosensor utilizing anion-induced fluorescence change” (d) Tong, H.; Zhou, G.; Wang, L.; Jing, X.; Wang, F.; Zhang, J. Tetrahedron Lett. 2003, 44, 131–134. “Novel highly selective anion chemosensors based on 2,5-bis(2-hydroxyphenyl)-1,3,4-oxadiazole”
9. (a) Waldbott, G. Clinical Toxicology 1981, 18, 531–541. “Mass intoxication from accidental overfluoridation of drinking water” (b) Matuso, S.; Kiyomiya, K.-I.; Kurebe, M. Arch. Toxicol. 1998, 72, 798–806. “Mechanism of toxic action of fluoride in dental fluorosis: whether trimeric G proteins participate in the disturbance of intracellular transport of secretory ameloblast exposed to fluoride” (c) Zhang, S.-W.; Swager, T. M. J. Am. Chem. Soc. 2003, 125, 3420–3421. “Fluorescent detection of chemical warfare agents: functional group specific ratiometric chemosensors” (d) Riggs, B. L. Bone and Mineral Research, 1984, 366–393. “Treatment of osteoporosis with sodium fluoride: an appraisal” (e) Laisalmi, M.; Kokki, H.; Soikkeli, A.; Markkanen, H.; Yli-Hankala, A.; Rosenberg, P.; Lindgren L. Acta. Anaesthesiol. Scand. 2006, 50, 982–987. “Effects of cigarette smoking on serum fluoride concentrations and renal function integrity after 1 MAC-h sevoflurane anaesthesia”
10. Peng, X.; Wu, Y.; Fan, J.; Tian, M.; Han, K. J. Org. Chem. 2005, 70, 10524–10531. “Colorimetric and ratiometric fluorescence sensing of fluoride: tuning selectivity in proton transfer”
11. Wu, J.-S.; Zhou, J.-H.; Wang, P.-F.; Zhang, X.-H.; Wu, S.-K. Org. Lett. 2005, 7, 2133–2136. “New fluorescent chemosensor based on exciplex signaling mechanism“
12. Melaimi, M.; Gabbï, P. J. Am. Chem. Soc. 2005, 127, 9680–9681. “A heteronuclear bidentate Lewis acid as a phosphorescent fluoride sensor”
13. Ghosh, S.; Choudhury, A. R.; Row, T. N. G.; Maitra, U. Org. Lett. 2005, 7, 1441–1444. “Selective and unusual fluoride Ion complexation by a steroidal receptor using OH…F– and CH…F– interactions: a new motif for anion coordination? “
14. Badugu, R.; Lakowicz, J. R.; Geddes, C. D. Sensor. Actuat. B-Chem. 2005, 104, 103–110. “A wavelength–ratiometric fluoride–sensitive probe based on the quinolinium nucleus and boronic acid moiety”
15. (a) Boiocchi, M.; Boca, L. D.; Esteban-Gómez, D.; Fabbrizzi, L. ; Licchelli, M.; Monzani, E. J. Am. Chem. Soc. 2004, 126, 16507–16514. “Nature of urea–fluoride interaction: incipient and definitive proton transfer” (b) Esteban-Gómez, D.; Fabbrizzi, L.; Licchelli, M. J. Org. Chem. 2005, 70, 5717–5720. “Why, on interaction of urea–based receptors with fluoride, beautiful colors develop”
16. Lee, C.-H.; Lee, J.-S.; Na H.-K.; Yoon, D.-W.; Miyaji, H.; Cho, W.-S.; Sessler, J. L. J. Org. Chem. 2005, 70, 2067–2074. “Cis-and trans-strapped calix[4]pyrroles bearing phthalamide linkers: synthesis and anion–binding properties”
17. These experiments were conducted by Dr. Srinivasan Selvi (Department of Chemistry, National Taiwan University).
18. Slevi, S.; Pu, S.-C.; Chen, Y.-M. ; Fang, J.-M. ; Chou, P.-T. J. Org. Chem. 2004, 69, 6674–6678. “Highly fluorescent pyteno[2,1-b]pyrroles: first syntheses, crystal structure, and intriguing photophysical properties”
19. Connors, K. A. Binding Constants Wiley: New York, 1987.
20. (a) Amendola, V.; Esteban-Gómez, D.; Fabbrizzi, L.; Licchelli, M. Acc. Chem. Res. 2006, 39, 343–353. “What anions do to N–H-containing receptors” (b) Kang, S. O.; Powell, D.; Day, V. W.; Bowman-James, K. Angew. Chem. Int. Ed. 2006, 45, 1921–1925. “Trapped bifluoride” (c) Wu, C.-Y.; Chen, M.-S.; Lin, C.-A.; Lin, S.-C.; Sun, S.-S. Chem. Eur. J. 2006, 12, 2263–2269. “Photophysical studies of anion-induced colorimetric response and amplified fluorescence quenching in dipyrrolylquinoxaline-containing conjugated polymers” (d) Black, C. B.; Andrioletti, B.; Try, A. C.; Ruiperez, C.; Sessler, J. L. J. Am. Chem. Soc. 1999, 121, 10438–10439. “Dipyrrolylquinoxalines: efficient sensors for fluoride anion in organic solution”
21. (a) Koradin, C.; Dohle, W.; Rodriguez, A. L.; Schmid, B.; Knochel, P. Tetrahedron, 2003, 59, 1571–1587. “Synthesis of polyfunctional indoles and related heterocycles mediated by cesium and potassium bases” (b) Kabalka, G. W.; Blankley, Wang, L.; Pagni, R. M. Tetrahedron, 2001, 57, 8017–8028. “Sonogashira coupling and cyclization reactions on alumina: a route to aryl alkynes, 2-substituted-benzo[b]furans and 2-substituted indoles” (c) Saulnier, M. G.; Frennesson, D. B.; Deshpande, M. S.; Vyas, D. M. Tetrahedron Lett. 1995, 43, 7841–7844. “Synthesis of a rebeccamycin–related indolo[2,3-a]carbazole by palladium(0) catalyzed polyannulation” (d) Cresp, T. M.; Ojima, J.; Sondheimer, F. J. Org. Chem. 1977, 12, 2130–2134. “Synthesis of methyl-substituted bisdehydro[13lannulenones. Conformational isomerism and ring current effects in conjugated 13-membered cyclic ketones”
22. (a) Ahlrichs, R.; Bar, M.; Haser, M.; Horn, H.; Kolmel, C. Chem. Phys. Lett. 1989, 162, 165–169. “Electronic structure calculations on workstation computers: the program system turbomole” (b) Treutler, O.; Ahlrichs, R. J. Chem. Phys. 1995, 102, 346–354. “Efficient molecular numerical integration schemes” (c) Deglmann, P.; Furche, F. J. Chem. Phys. 2002, 117, 9535–9538. “Efficient characterization of stationary points on potential energy surfaces” (d) Haser, M.; Ahlrichs, R.; Baron, H. P.; Weis, P.; Horn, H. Theoret. Chim. Acta. 1992, 83, 455–470. “Direct computation of second-order SCF properties of large molecules on workstation computers with an application to large carbon clusters”
23. Huntington’s Disease, Bates, G., Harper, P. S., Jones, L., Eds.; Oxford University Press, Oxford, 2002.
24. The Huntington’s Disease Collaborative Research Group Cell 1993, 72, 971–983. “A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes”
25. Blum, D.; Hourez, R.; Galas, M.-C.; Popoli, P.; Schiffmann, S. N. Lancet Neurology 2003, 2, 366–374. “Adenosine receptors and Huntington’s disease: implications for pathogenesis and therapeutics”
26. (a) Jankovic, J.; Beach, J. Neurology 1997, 48, 358–362. “Long-term effects of tetrabenazine in hyperkinetic movement disorders” (b) van Vugt, J. P. P.; Siesling, S.; Vergeer, M.; van der Velde, E. A.; Roos, R. A. C. J. Neurol. Neurosur. Ps. 1997, 63, 35–39. “Clozapine versus placebo in Huntington’s disease: a double blind randomised comparative study” (c) Kieburtz, K.; Feigin, A.; McDermott, M.; Como, P.; Abwender, D.; Zimmerman, C.; Hickey, C.; Orme, C.; Claude, K.; Sotack, J.; Greenamyre, J. T.; Dunn, C.; Shoulson, I. Movement Disorders 1996, 11, 273–277. “A controlled trial of remacemide hydrochloride in Huntington’s disease” (d) Feigin, A.; Kieburtz, K.; Como, P.; Hickey, C.; Claude, K.; Abwender, D.; Zimmerman, C.; Steinberg, K.; Shoulson, I. Movement Disorders 1996, 11, 321–323. “Assessment of coenzyme Q10 tolerability in Huntington’s disease” (e) Bachoud-Levi, A.-C.; Remy, P.; Nguyen, J.-P.; Brugieres, P.; Lefaucheur, J.-P.; Bourdet, C.; Baudic, S.; Gaura, V.; Maison, P.; Haddad, B.; Boisse, M.-F.; Grandmougin, T.; Jeny, R.; Bartolomeo, P.; Barba, G. D.; Degos, J.-D.; Lisovoski, F.; Ergis, A.-M.; Pailhous, E.; Cesaro, P.; Hantraye, P.; Peschanski, M. Lancet 2000, 356, 1975–1979. “Motor and cognitive improvements in patients with Huntington’s disease after neural transplantation”
27. (a) Fredholm, B. B.; Ijzerman, A. P.; Jacobson, K. A.; Klotz, K.-N.; Linden, J. Pharmacl. Rev. 2001, 54, 527–552. “International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors” (b) Sebastião, A. M.; Ribeiro, J. A. Prog. Neurobiol. 1996, 46, 167–189. “Adenosine A2A receptor–mediated excitatory actions on the nervous system” (c) Dunwiddie, T. V.; Masino, S. A. Annu. Rev. Neurosci. 2001, 24, 31–55. “The role and regulation of adenosine in the central nervous system”
28. (a) Kase, H. Biosci. Biotechnol. Biochem. 2001, 65, 1447–1457. “New aspects of physiological and pathophysiological functions of adenosine A2A receptor in basal ganglia” (b) Richardson, P. J.; Kase, H.; Jenner, P. G. Trends Pharmacol. Sci. 1998, 18, 338–344. “Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson’s disease”
29. (a) Huang, N.-K.; Lin, Y.-W.; Huang, C.-L.; Messing, R. O.; Chern, Y. J. Biol. Chem. 2001, 276, 13838–13846. “Activation of protein kinase A and atypical protein kinase C by A2A adenosine receptors antagonizes apoptosis due to serum deprivation in PC12 cells” (b) Chiang, M.-C.; Lee, Y.-C.; Huang, C.-L.; Chern, Y. J. Biol. Chem. 2005, 280, 14331–14340. “cAMP-response element–binding protein contributes to suppression of the A¬2A adenosine receptor promoter by mutant Huntingtin with expanded polyglutamine residues” (c) Mangiarini, L.; Sathasivam, K.; Seller, M.; Cozens, B.; Harper, A.; Hetherington, C.; Lawton, M.; Trottier, Y.; Lehrach, H.; Davies, S. W.; Bates, G. P. Cell, 1996, 87, 493–506. “Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice” (d) Chou, S.-Y.; Lee, Y.-C.; Chen, H.-M.; Chiang, M.-C.; Lai, H.-L.; Chang, H.-H.; Wu, Y.-C.; Sun, C.-N.; Chien, C.-L.; Lin, Y.-S.; Wang, S.-C.; Tung, Y.-Y.; Chang, C.; Chern, Y. J. Neurochem. 2005, 93, 310–320. “CGS21680 attenuates symptoms of Huntington’s disease in a transgenic mouse model”
30. (a) Noji, T.; Karasawa, A.; Kusaka, H. E. Eur. J. Pharmacol. 2004, 495, 1–16. “Adenosine uptake inhibitors” (b) King, A. E.; Ackley, m. A.; Cass, C. E.; Young, J. D.; Baldwin, S. A. Trends Pharmacol. Sci. 2006, 27, 416–425. “Nucleoside transporters: from scavengers to novel therapeutic targets” (c) Baldwin, S. A.; Mackey, J. R.; Cass, C. E.; Young, J. D. Mol. Med. Today 1999, 5, 216–224. “Nucleoside transporters: molecular biology and implications for therapeutic development”
31. (a) Shi, M. M.; Wu, J. R.; Lee, C.; Young, J. D. Biochem. Biophys, Res. Commun. 1984, 118, 594–600. “Adenosine uptake inhibitors” (b) Castillo-Melendez, M.; Jarrott, B.; Lawrence, A. J. J. Auton Nerv. Syst. 1996, 84, 36–42. “Radioligand binding and autoradiographic visualization of adenosine transport sites in human inferior vagal ganglia and their axonal transport along rat vagal afferent neurons.” (c) Parkinson, F. E.; Rudolphi, K. A.; Fredholm, B. B. Gen. Pharmacol. 1994, 25, 1053–1058. “A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes”
32. (a) Zhang, H.-Y. FEBS Lett. 2005, 579, 5260–5264. “One-compound-multiple- targets strategy to combat Alzheimer’s disease” (b) Cavalli, A.; Bolognesi, M. L.; Capsoni, S.; Andrisano, V.; Bartolini, M.; Margotti, E.; Cattaneo, A.; Recanatini, M.; Melchiorre, C. Angew. Chem. Int. Ed. 2007, 46, 3689–3692. “A small molecule targeting the multifactorial nature of Alzheimer’s disease”
33. (a) Huang, N.-K.; Chern, Y.; Fang, J.-M.; Lin, C.-I.; Chen, W.-P.; Lin, Y.-L. J. Nat. Prod., 2007, 70, 571–574. “Neutoprotective principles from Gastrodia eleta” (b) Huang, N. K.; Lin, Y. L.; Cheng, J. J.; Lai, W. L. Life Sci., 2004, 75, 1649–1657. “Gastrodia eleta prevents rat pheochromocytoma cells from serum-deprived apoptosis: the role of the MAPK family”
34. (a) An, S. J.; Park, S. K.; Hwang, I. K.; Choi, S. Y.; Kim, S. K.; Kwon, O. S.; Jung, S. J.; Baek, N. I.; Lee, H. Y.; Won, M. H.; Kang, T. C. J. Neurosci. Res., 2003, 71, 534–543. “Gastrodin decreases immunoreactivities of γ-aminobutyric acid shunt enzymes in the hippocampus of seizure-sensitive gerbils” (b) Kim, H. J.; Moon, K. D.; Oh, S. Y.; Kim, S. P.; Lee, S. R. Neurosci. Lett., 2001, 314, 65–68. “Ether fraction of methanol extracts of Gastrodia elata, a traditional medicinal herb, protects against kainic acid-induced neuronal damage in the mouse hippocampus” (c) Kim, H. J.; Lee, S. R.; Moon, K. D. Phytother. Res., 2003, 17, 909–912. “Ether fraction of methanol extracts of Gastrodia elata, medicinal herb protects against neuronal cell damage after transient global ischemia in gerbils” (d) Kim, H. J.; Moon, K. D.; Lee, D. S.; Lee, S. H. J. Ethnopharmacol,. 2003, 84, 95–98. “Ethyl ether fraction of Gastrodia elata Blume protects amyloid β peptide-induced cell death” (e) Hsieh, C. L.; Chiang, S. Y.; Cheng, K. S.; Lin, Y. H.; Tang, N. Y.; Lee, C. J.; Pon, C. Z.; Hsieh, C. T. Am. J. Chin. Med., 2001, 29, 331–341. “Anticonvulsive and free radical scavenging activities of Gastrodia elata Bl. In kainic acid-treated rats” (f) Hsieh, C. L.; Chang, C. H.; Chiang, S. Y.; Li, T. C.; Tang, N. Y.; Pon, C. Z.; Hsieh, C. T.; Lin, J. G. Life Sci., 2000, 67, 1185–1195. “Anticonvulsive and free radical scavenging activities of vanillyl alcohol in ferric chloride-induced epileptic seizures in Sprague-Dawley rats”
35. Chern, Y.-J. Institute of Biomedical Sciences, Academia Sinica.
36. Huang, N.-K. National Research Institute of Chinese Medicine.
37. Lin, J.-H. Department of Pharmacy, National Taiwan University.
38. (a) Rukenstein, A.; Rydel, R. E.; Greene, L. A. J. Neurosci. 1991, 11, 2552–2563. “Multiple agents rescue PC12 cells from serum-free cell death by translation- and Transcription-independent mechanisms” (b) Batistatou, A.; Greene, L. A. J. Cell Biol. 1991, 115, 461–471. ”Aurintricarboxylic acid rescues PC12 cells and sympathetic neurons from cell death caused by nerve growth factor deprivation: correlation with suppression of endonuclease activity”
39. (a) Mosmann, T. J. Immunol. Meth. 1983, 65, 55–63. “Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays” (b) Liu, Y. Prog. Neuro-psychopharmacol. Biol. Psychiat. 1999, 23, 377–395. “Understanding the biological activity of amyloid β proteins in vitro: from inhibited cellular MTT reduction to altered cellular cholesterol homeostatis”
40. (a) Kurogi, Y.; Güner, O. F. Curr. Med. Chem., 2001, 8, 1035–1055. “Pharmacophore modeling and three-dimensional database searching for drug design using Catalyst” (b) Guner, O.; Clement, O.; Kurogi, Y. Curr. Med. Chem., 2004, 11, 2991–3005. “Pharmacophore modeling and three dimensional database searching for drug design using Catalyst: recent advances” (c) Debnath, A. K. Curr. Pharm. Design, 2005, 11, 3091–3110. “Application of 3D-QSAR techniques in anti-HIV-1 drug design – an overview” (d) Purushottamachar, P.; Khandelwal, A.; Chopra, P.; Maheshwari, N.; Gediya, L. K.; Vasaitis, T. S.; Bruno, R. D.; Clementc, O. O.; Njara, V. C. O. Bioorg. Med. Chem., 2007, 15, 3413–3421. “First pharmacophore-based identification of androgen receptor down-regulating agents: discovery of potent anti-prostate cancer agents” (e) Yu, H.; Wang, Z.; Zhang, L.; Zhanga, J.; Huang, Q. Bioorg. Med. Chem. Lett., 2007, 17, 2126–2133. “Pharmacophore modeling and in silico screening for new KDR kinase inhibitors” (f) Wei, J.; Wang, S.; Gao, S.; Dai, X.; Gao, Q. J. Chem. Inf. Model., 2007, 47, 613–625. “3D–pharmacophore models for selective A2A and A2B adenosine receptor antagonists”
41. Cristalli, G.; Cacciari, B.; Ben, D. D. ; Lambertucci, C. ; Moro, S. ; Spalluto, G. ; Volpini, R. ChemMedChem, 2007, 2, 260–281. “Highlights on the development of A2A adenosine receptor agonists and antagonists”
42. (a) Cusack, N. J.; Hourani, S. M. O. Br. J. Pharmacol. 1981, 72, 443– 447. “5'-N-Ethylcarboxamidoadenosine: A potent inhibitor of human platelet aggregation” (b) de Zwaart, M.; Link, R.; von Friftag Drabbe-KGnzel, J. K.; Cristalli, G.; Jacobson, K. A.; Townsend-Nicholson, A.; IJzerman, A. P. Nucleosides Nucleotides 1998, 17, 969–985. “A functional screening of adenosine analogues at the adenosine A2B receptor: a search for potent agonists”
43. (a) Ohno, M.; Gao, Z.-G.; van Rompaey, P.; Tchilibon, S.; Kim, S.-K.; Harris, B. A.; Gross, A. S.; Duong, H. T.; van Calenbergh, S.; Jacobson, K. A. Bioorg. Med. Chem. 2004, 12, 2995 –3007. “Modulation of adenosine receptor affinity and intrinsic efficacy in adenine nucleosides substituted at the 2-position” (b) Francis, J. E.; Webb, R. L.; Ghai, G. R.; Hutchison, A. J.; Moskal, M. A.; de Jesus, R.; Yokoyama, R.; Rovinski, S. L.; Contardo, N.; Dotson, R.; Barclay, B.; Stone, G. A.; Jarvis, M. F. J. Med. Chem. 1991, 34, 2570–2579. “Highly selective adenosine A2 receptor agonists in a series of N-alkylated 2-aminoadenosines” (c) Stein, H. H.; Somani, P.; Prasad, R. N. Ann. N. Y. Acad. Sci. 1975, 255, 380–389. “Cardiovascular effects of nucleoside analogs” (d) Daly, W.; Padgett, W. L.; Secunda, S. I.; Thompson, R. D.; Olsson, R. A. Pharmacology 1993, 46, 91–100. “Structure-activity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors” (e) Hasan, A.; Hussain, T.; Mustafa, S. J.; Srivastava, P. C. Bioconjugate Chem. 1994, 5, 364–369. “2-Substituted thioadenine nucleoside and nucleotide analogues: synthesis and receptor subtype binding affinities”
44. Cristalli, G. ; Franchetti, P.; Grifantini, M.; Vittori, S.; Klotz, K. N.; Lohse, M. J. J. Med. Chem. 1988, 31, 1179–1183. “Adenosine receptor agonists: synthesis and biological evaluation of 1-deaza analogues of adenosine derivatives”
45. Lehninger Principles of Biochemistry, Nelson, D. L., Cox, M. M., Eds.; Worth Publishers, New York, 2000. p 449–458.
46. (a) Chern, Y.; Lai, H.-L.; Fong, J. C.; Liang, Y. Mol. Pharmacol. 1993, 44, 950–958. “Multiple mechanisms for desensitization of A¬2A adenosine receptor–mediated cAMP elevation in rat pheochromocytoma PC12 cells” (b) Chern, Y.; Chiou, J.-Y.; Lai, H.-L.; Tsai, M.-H. Mol. Pharmacol. 1995, 48, 1–8. “Regulation of adenylyl cyclase type VI activity during desensitization of the A¬2A adenosine receptor–mediated cyclic AMP response: role for protein phosphatase 2A”
47. (a) Griefiths, M.; Beaumont, N.; Yao, S. Y. M.; Sundaram, M.; Boumah, C. E.; Davies, A.; Kwong, F. Y. P.; Coe, I.; Cass, C. E.; Young, J. D.; Baldwin, S. A. Nat. Med. 1997, 3, 89–93. “Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs” (b) Ward, J. L.; Sherali, A.; Mo, Z.-P.; Tse, C.-M. J. Biol. Chem. 2000, 275, 8375–8381. “Kinetic and pharmacological properties of cloned human equilibrative nucleoside transporters, ENT1 and ENT2, stably expressed in nucleoside transporter-deficient PK15 cells”
48. (a) Paul, B.; Chen, M. F.; Paterson, A. R. P. J. Med. Chem. 1975, 18, 968–973. “Inhibitors of nucleoside transport. A structure-activity study using human erythrocytes” (b) Agbanyo, F. R.; Vijayalakshmi, D.; Craik, J. D.; Gati, W. P.; McAdam, D. P.; Asakura, J.; Robins, M. J.; Paterson, A. R. P.; Cass, C. E. Biochem. J. 1990, 270, 605–614. “5’-S-(2-Aminoethyl)-N6-(4-nitrobenzyl)-5’-thioadenosine (SAENTA), a novel ligand with high affinity for polypeptides associated with nucleoside transporter”
49. (a) Microwave Synthesis: Chemistry at the Speed of Light, Hayes, B. L., Eds.; CEM Publishing, U.S.A., 2002. (b) Luo, G.; Chen, L.; Poindexter, G. S. Tetrahedron Lett., 2002, 43, 5739–5742. “Microwave-assisted synthesis of aminopyrimidines” (c) Fang, W.-P.; Cheng, Y.-T.; Cheng, Y.-R.; Cherng, Y.-J. Tetrahedron, 2005, 61, 3107–3113. “Synthesis of substituted uracils by the reactions of halouracils with selenium, sulfur, oxygen and nitrogen nucleophiles under focused microwave irradiation”
50. (a) Na1gele, E.; Schelhaas, M.; Kuder, N.; Waldmann, H. J. Am. Chem. Soc. 1998, 120, 6889–6902. “Chemoenzymatic synthesis of N-Ras lipopeptides“ (b) Mikawa, H. Bull. Chem. Soc. Jpn. 1954, 27, 50–53. “Hydrogen sulfide cookings of p-oxybenzyl alcohols. I.” (c) United States Rubber Company, US 3322649, 1967, “Protection of organic material from oxidative deterioration with bis(3,5-dihydrocarbyl-4-hydroxybenzyl) sulfoxides.“
51. (a) Trivedi, B. K.; Blankley, C. J.; Bristol, J. A.; Hamilton, H. W.; Patt, W. C.; Kramer, W. J.; Johnson, S. A.; Bruns, R. F.; Cohen, D. M.; Ryan, M. J. J. Med. Chem. 1991, 34, 1043–1049. “N6-Substituted adenosine receptor agonists: potential antihypertensive agents“ (b) Golisade, A.; Wiesner, J.; Herforth, C.; Jomaab, H.; Linka, A. Bioorg. Med. Chem. 2002, 10, 769–777. “Anti-malarial activity of N6-substituted adenosine derivatives. Part I” (c) Koyama, H.; Boueres, J. K.; Han, W.; Metzger, E. J.; Bergman, J. P.; Gratale, D. F.; Miller, D. J.; Tolman, R. L.; MacNaul, K. L.; Berger, J. P.; Doebber, T. W.; Leung, K.; Moller, D. E.; Hecka, J. V.; Sahooa, S. P. Bioorg. Med. Chem. Lett. 2003, 13, 1795–1799. “Discovery of 3-amino-4-chlorophenyl P1 as a novel and potent benzamidine mimic via solid-phase synthesis of an isoxazoline library” (d) Gannett, P. M.; Nagel, D. L.; Reilly, P. J.; Lawson, T.; Sharpe, J.; Toth, B. J. Org. Chem. 1988, 53, 1064–1071. “The Capsaicinoids: their separation, synthesis, and mutagenicity”
52. Hampton, A.; Kappler, F. J. Med. Chem. 1990, 33, 2545–2551. “Approaches to isozyme-specific inhibitors. 17. Attachment of a selectivity-inducing substituent to a multisubstrate adduct. Implications for facilitated design of potent, isozyme-selective inhibitors” | en |